ENFORTUMAB VEDOTIN for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 31 adverse event reports in the FDA FAERS database where ENFORTUMAB VEDOTIN was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for ENFORTUMAB VEDOTIN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Rash | 173 | 12.1% | 24 | 48 |
| Neuropathy peripheral | 172 | 12.1% | 9 | 30 |
| Malignant neoplasm progression | 166 | 11.7% | 70 | 53 |
| Decreased appetite | 106 | 7.4% | 20 | 60 |
| Diarrhoea | 96 | 6.7% | 22 | 59 |
| Pruritus | 83 | 5.8% | 7 | 28 |
| Alopecia | 78 | 5.5% | 7 | 15 |
| Inappropriate schedule of product administration | 73 | 5.1% | 5 | 33 |
| Pyrexia | 70 | 4.9% | 10 | 50 |
| Hyperglycaemia | 69 | 4.8% | 22 | 41 |
| Nausea | 67 | 4.7% | 14 | 41 |
| Taste disorder | 58 | 4.1% | 5 | 13 |
| Fatigue | 57 | 4.0% | 4 | 19 |
| Malaise | 57 | 4.0% | 7 | 23 |
| Neutropenia | 56 | 3.9% | 10 | 24 |
Other Indications for ENFORTUMAB VEDOTIN
Transitional cell carcinoma (649)
Bladder cancer (225)
Product used for unknown indication (149)
Transitional cell carcinoma metastatic (123)
Metastatic carcinoma of the bladder (35)
Malignant neoplasm of renal pelvis (30)
Transitional cell cancer of the renal pelvis and ureter (26)
Ureteric cancer (19)
Adenocarcinoma of colon (14)
Rectal adenocarcinoma (11)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
AVELUMAB (104)
DURVALUMAB (88)
NIVOLUMAB (80)
ENFORTUMAB VEDOTIN-EJFV (68)